Arcutis Presents ZORYVE Data At EADV Congress
Benzinga News-desk 3 weeks ago
News
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and DERMIS-1/2 trials
- Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited
- New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE’s efficacy and symptom improvements across the body in individuals with psoriasis
- Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis
- Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions